Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
最新数据
US$1.06
−US$0.06 · -5.36%
盘中时间采用ET。市场数据可能有所延迟。
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 4109.5万 USD | 3608.4万 USD | 1575.9万 USD | — |
| 销货成本 | 11.6万 USD | — | — | — | — |
| 毛利 | −11.6万 USD | 4109.5万 USD | 3608.4万 USD | 1575.9万 USD | — |
| 研究与开发 | 1284.3万 USD | 3742.8万 USD | 3703.9万 USD | 3754.7万 USD | 2637.9万 USD |
| 销售、一般及管理费用 | 1079.1万 USD | 1193.6万 USD | 1356.7万 USD | 1723.9万 USD | 1140.7万 USD |
| 营业费用 | 2363.4万 USD | 4936.4万 USD | 5060.6万 USD | 7783.5万 USD | 3778.6万 USD |
| 利息收入 | 83.3万 USD | 138.1万 USD | 233.4万 USD | 42万 USD | 5.7万 USD |
| 利息支出 | — | — | 49.1万 USD | 105.3万 USD | 107.3万 USD |
| 折旧和摊销 | 11.6万 USD | 13.7万 USD | 12.6万 USD | 11.8万 USD | 7.2万 USD |
| 营业利润 | −2363.4万 USD | −826.9万 USD | −1452.2万 USD | −6207.6万 USD | −3778.6万 USD |
| 净利润 | −2239.8万 USD | −806.7万 USD | −1333.5万 USD | −6242.8万 USD | −3898万 USD |
公司数据更新于 2026年11月22日。
第三方分析师预期可能变化,并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。